News | December 23, 2025
Cupid reduces promoter pledged stake to 20%
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
NUFYMCO BLA has been approved by the USFDA
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
The company also reported significant progress toward its internally defined Sustainable Development Goals
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
